AYX1: Completed Phase II enrollment

Adynxx completed enrollment of 102 patients in a double-blind, placebo-controlled, U.S. Phase II trial evaluating single intrathecal injections of 110 and 330 mg AYX1 prior to unilateral total knee ar...